Go

Find A Location

Search

Clinical Research Lab (CRL)

Not all clinical trials have approval to be posted on this web site; however trials will be posted when approval has been granted.  Contact Ms. Rueweler if you would like a trial posted ruewelerp@mir.wustl.edu  

ACRIN 6685 - PET/CT Staging of Head & Neck and it's Impact on the N0 Neck Surgical Treatment

Purpose: To determine the negative predictive value of PET/T for the N0 neck based pathologic sampling of the neck lymph nodes and determine PET/CT's potential to change treatment of the N0 neck.

To Qualify:  Newly diagnosis of head and neck and neck squamous cell carcinoma considered for surgical resection with at least one side of nect clinically N0.

For additional information contact Robin Haverman at (314) 747-1624 or havermanr@mir.wustl.edu

 

ACRIN 6690 - Prospective, Multicenter Comparison of Multiphase Contrast-Enhanced CT and Multiphase Contrast-Enhanced MRI for Diagnosis of Hepatocellular Carcinoma and Liver Transplant Allocation

Purpose: The main objective of the ACRIN 6690 trial is to compare the accuracy of radiologic staginf of HCC by CT and MRI with the reference standrd provided by explant pathology workup/staging of participants who undergo liver transplantation for treatment of HCC. Primary analysis will compare CT to MRI results at the lesion level using core laboratory interpretations of the imaging studies; secondary analysis will be performed at the patient level.  Patients diagnosed with HCC and listed for liver transplant surgery with priority MELD (Model for End-Stage Liver Disease) points based on the cancer diagnosis will participate.  Patients may be waiting for a liver from a deceased donor to become available or be scheduled to undergo a liver transplant.

To Qualify:

  • A living donor adult liver transplant
  • Patients must enroll in the trial within 30 days after initial listing with HCC-exception points to the United Network for Organ Sharing (UNOS) waitlist

For additional information contact Ruth Holdener at (314) 747-2034 or holdenerr@mir.wustl.edu

 

EPOCH-102 - A Phase III Clinical Trial Evaluating TheraSphere® in Patients with Metastatic Colorectal Carcinoma of the Liver who have Failed First Line Chemotherapy

Purpose: To evaluate the efficacy and safety of TheraSphere® in patients with metastatic colorectal cancer of the liver scheduled to receive second line chemotherapy.

To Qualify:

  • Must have colorectal cancer with unresetable metastatic disease to the liver (unresectable unilobar or bilobar disease) who have disease progression with oxaliplatin or irinotecan based first line chemotherapy. 
  • Must be eligible to receive second-line standard standard-of-care chemotherapy with either
    1. an oxaliplatin-based chemotherapy regimen, or
    2. an irinotecan-based chemotherapy regimen

For additional information contact Robin Haverman at (314) 747-1624 or havermanr@mir.wustl.edu

For additional information on more actively recruiting studies involving CRL, please contact Robin Haverman at (314) 747-1624 or havermanr@mir.wustl.edu